SCHEMBL3884880

SCHEMBL3884880

CCn1ccc2cc(-c3cc(CCC(=O)O)cc(OC)c3OC3CCCC3)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 3/20 0.45
TUBB P07437 3/20 0.45
TUBA3C P0DPH7 3/20 0.45
TUBA1B P68363 3/20 0.45
TUBA4A P68366 3/20 0.45
TUBB4B P68371 3/20 0.45
TUBB3 Q13509 3/20 0.45
TUBB2A Q13885 3/20 0.45
TUBB8 Q3ZCM7 3/20 0.45
TUBA3E Q6PEY2 3/20 0.45
TUBA1A Q71U36 3/20 0.45
TUBA1C Q9BQE3 3/20 0.45
TUBB6 Q9BUF5 3/20 0.45
TUBB2B Q9BVA1 3/20 0.45
TUBB1 Q9H4B7 3/20 0.45
THRB P10828 2/20 0.44
THRA P10827 1/20 0.44
FFAR4 Q5NUL3 5/20 0.40
KMT2A Q03164 2/20 0.37
PPARG P37231 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3894597 0.91 TUBB4A (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3891246 0.89 THRA (0.45) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3881651 0.89 THRA (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3884910 0.89 FFAR4 (0.45) THRBTHRAFFAR4PPARGNR1H2
SCHEMBL3893247 0.88 THRA (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3882213 0.88 THRA (0.46) THRBTHRAFFAR4PPARGNR1H2
SCHEMBL3883490 0.86 FFAR4 (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3882214 0.86 FFAR4 (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3896107 0.85 THRB (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3896105 0.85 THRB (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 TUBB4A 4418/4885TUBB 4211/4885TUBA3C 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.